Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasma Exchange with Human Serum Albumin 5% in Acute-on-Chronic Liver Failure
2016-001787-10Phase 3Active
- Sponsor
- Instituto Grifols
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of albumin (human) in Cirrhosis, acute-on-chronic liver failure (ACLF) and decompensated cirrhosis (2 arms), sponsored by Instituto Grifols. Primary endpoint: 90-day overall survival. Started Aug 2018; status: active.
02
Drugs
albumin (human)
03
Conditions
Cirrhosisacute-on-chronic liver failure (ACLF)decompensated cirrhosis
Beyond the preview
Go deeper on 2016-001787-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001787-10.